Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. $1177.HK
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS21
PHASE 3 / 2-37
RECRUITING18
READOUTS ≤12 MONTHS10
READOUT SLIPPED >6 MO27%
Delay Index: of 15 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. on the live radar map → 📅 $1177.HK readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine NCT06825494 |
P1/2 | Recruiting | Advanced Solid Tumor | 194 | 2026-03 |
| TQB2102 for injection NCT06798207 |
P2 | Recruiting | Gynecological Tumors | 170 | 2026-05 |
| TQB2102 for injection NCT06496490 |
P2 | Recruiting | Non-Small Cell Lung Cancer | 270 | 2026-06 (+8 mo) |
| TQB2102 for injection NCT06452706 |
P2 | Recruiting | Breast Cancer | 42 | 2026-06 |
| Recombinant human activated coagulation factor VIII for injection NCT06297655 |
P3 | Active, not recruiting | Hemophilia A | 60 | 2026-07 (+15 mo) |
| TQB2922 injection ± TAS-102 tablets NCT07044908 |
P1/2 | Recruiting | RAS/BRAF Wild Type Colorectal Cancer | 72 | 2026-07 |
| TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy NCT06767800 |
P2 | Recruiting | Gastroesophageal Adenocarcinoma | 204 | 2026-09 |
| TQB2868 injection NCT06767813 |
P2 | Recruiting | Pancreatic Neoplasms | 80 | 2026-11 (+20 mo) |
| NCT06569524 NCT06569524 |
P2 | Recruiting | Non-alcoholic Steatohepatitis | 120 | 2026-12 |
| TQC2938 injection NCT06789289 |
P2 | Active, not recruiting | Chronic Obstructive Pulmonary Disease | 256 | 2027-03-17 (-9 mo) |
| TQB2102 for injection NCT06431490 |
P1/2 | Recruiting | Biliary Tract Cancer | 102 | 2027-05 (+24 mo) |
| TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection NCT07653685 |
P1/2 | Recruiting | Colorectal Cancer | 71 | 2027-06 |
| TQB2102 Injection NCT07483684 |
P3 | Not yet recruiting | HER2 IHC3+ Advanced Colorectal Cancer | 142 | 2027-08 |
| TQB2916 Injection NCT06962267 |
P2 | Recruiting | Pancreatic Cancer | 50 | 2027-08 |
| TQH3906 Capsule NCT07406035 |
P2 | Recruiting | Psoriatic Arthritis | 156 | 2027-08 |
| TQB2102 for injection NCT07043725 |
P3 | Recruiting | HER2-positive Breast Cancer | 544 | 2027-09 |
| TQH3906 capsules NCT07724366 |
P3 | Recruiting | Psoriasis | 400 | 2027-09 |
| TQB2930 injection+TQB2102 for injection NCT07512583 |
P1/2 | Recruiting | Advanced Solid Tumor | 178 | 2028-03 |
| TQB2102 Injection NCT07008976 |
P3 | Recruiting | Metastatic Breast Cancer | 246 | 2028-03 |
| TQB2930+ chemotherapy NCT07047365 |
P3 | Recruiting | HER2-positive Advanced Breast Cancer | 416 | 2028-06 |
| TQB2102 for Injection NCT07003074 |
P3 | Recruiting | Breast Cancer | 642 | 2029-07 |